NASDAQ · EPRX
Eupraxia Pharmaceuticals Inc.
$7.25-$0.13 (-1.76%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.21% below the high.
Loading market information…
NASDAQ · AARD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aardvark Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 91.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aardvark Therapeutics, Inc. Common Stock’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.72. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aardvark Therapeutics, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 31, 2025 | -$0.44-6.1% vs estimate | $0.00 |
|---|
| Q3 2024 | Sep 30, 2024 | -$0.32 | $0.00 |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $2.75.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.25-$0.13 (-1.76%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.21% below the high.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$3.14-$0.07 (-2.18%)
Nautilus Biotechnolgy, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.15% below the high.
$7.44+$0.32 (+4.49%)
Avalo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.34% below the high.
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
$11.15-$0.40 (-3.46%)
Enanta Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.99% below the high.
$2.09-$0.04 (-1.88%)
Foghorn Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.54% below the high.
$1.89-$0.09 (-4.55%)
Pyxis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.95% below the high.
